01—Abstract
Summary
Summary of the 8-K filed May 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported first-quarter 2025 results for the period ended March 31, 2025, with total revenues of $572.6 milliona, up from $515.3 million a year earlier.
INGREZZA net product sales were $545.2 millionb, which the company states represents 8% growth compared with the first quarter of 2024, driven by record new patient starts and improved gross-to-net dynamics. CRENESSITY, in its initial launch, generated net product sales of $14.5 million and 413 total patient enrollment start forms. GAAP net income fell to $7.9 million, or $0.08 per diluted share, from $43.4 million, or $0.42 per diluted share.
Non-GAAP net income was $71.5 millionc, or $0.70 per diluted share, compared with $124.8 million, or $1.20 per diluted share. The decline reflects higher R&D and SG&A expense, including a $45 million development milestone in R&D tied to the start of the osavampator Phase 3 program, and a $31 million loss from changes in fair values of equity investments. The company reaffirmed its 2025 guidance, including INGREZZA net product sales of $2.5 to $2.6 billion, GAAP R&D expense of $960 to $1,010 million, and GAAP SG&A expense of $1,110 to $1,130 million.
Management highlighted the initiation of two Phase 3 registrational programs, for osavampator in major depressive disorder and NBI-1117568 in schizophrenia, along with Phase 1 studies for NBI-921355 and NBI-1140675. Total cash, cash equivalents, and marketable securities were $1,758.8 milliond at March 31, 2025, versus $1,815.6 million at December 31, 2024. The company completed a $300 million accelerated share repurchase on February 5, 2025, and had repurchased $150 million under a second $500 million program, with $350 million remaining.
The filing also notes the appointment of Sanjay Keswani, M.D., as Chief Medical Officer effective June 2, 2025, and top-line data from the Phase 4 KINECT-PRO study of INGREZZA in tardive dyskinesia. Management described the combination of INGREZZA and CRENESSITY as a solid foundation for near- and long-term revenue growth.
02—Key points
Key Highlights
- Total revenues rose to $572.6 million from $515.3 million, with INGREZZA net product sales of $545.2 million (8% growth year over year) and CRENESSITY net product sales of $14.5 million in its launch quarter.
- GAAP net income declined to $7.9 million ($0.08 per diluted share) from $43.4 million ($0.42), while non-GAAP net income was $71.5 million ($0.70 per diluted share) versus $124.8 million ($1.20).
- GAAP R&D expense increased to $263.2 million from $159.4 million, including a $45 million development milestone primarily tied to the osavampator Phase 3 initiation; GAAP SG&A was $276.5 million versus $243.1 million.
- 2025 guidance was reaffirmed: INGREZZA net product sales of $2.5 to $2.6 billion, GAAP R&D of $960 to $1,010 million, and GAAP SG&A of $1,110 to $1,130 million.
- Two Phase 3 registrational programs were initiated: osavampator for major depressive disorder and NBI-1117568 for schizophrenia, alongside Phase 1 studies of NBI-921355 and NBI-1140675.
- Capital returns continued: a $300 million accelerated share repurchase was completed on February 5, 2025, and $150 million of a $500 million second program had been repurchased by March 31, 2025, leaving $350 million authorized.
- Cash, cash equivalents, and marketable securities totaled $1,758.8 million at March 31, 2025, down from $1,815.6 million at December 31, 2024.
03—Questions
Frequently Asked Questions
How did INGREZZA perform in the first quarter of 2025?
INGREZZA net product sales were $545.2 million, compared with $506.0 million in the first quarter of 2024. The company states this represents 8% growth, driven by record new patient starts and improved gross-to-net dynamics, and expanded formulary access now covers two-thirds of tardive dyskinesia and Huntington’s disease Medicare beneficiaries.
How is the CRENESSITY launch progressing?
CRENESSITY generated first-quarter 2025 net product sales of $14.5 million and 413 total patient enrollment start forms. The company reports approximately 70% reimbursement coverage for dispensed scripts and describes the initial patient demand as strong.
Why did GAAP earnings decline compared with the prior year?
GAAP net income was $7.9 million ($0.08 per diluted share) versus $43.4 million ($0.42) a year earlier. The filing attributes the change to higher operating expenses supporting the R&D portfolio, CRENESSITY launch costs, and the INGREZZA sales force expansion, plus a $45 million development milestone in R&D and a $31 million loss from changes in fair values of equity investments.
Did the company change its 2025 financial guidance?
No. Neurocrine reaffirmed its 2025 guidance, including INGREZZA net product sales of $2.5 to $2.6 billion, GAAP R&D expense of $960 to $1,010 million, and GAAP SG&A expense of $1,110 to $1,130 million. R&D guidance includes $60 million of expense for development milestones tied to collaborations with Takeda and Nxera.
What are the company's capital allocation actions?
The company completed a $300 million accelerated share repurchase on February 5, 2025. Under a second program authorized February 21, 2025 for up to $500 million, it had repurchased $150 million as of March 31, 2025, with $350 million remaining. Cash, cash equivalents, and marketable securities were $1,758.8 million at quarter end.
04—Continue